Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small-molecule therapies based on cancer epigenetics. The company’s two lead clinical programs are CPI-1205 and CPI-0610. It plans to use proceeds from its recent financing to advance multiple clinical trials across its portfolio, including the ProSTAR and ORIOn-E trials for CPI-1205, which aim to enhance androgen inhibitors in metastatic castration-resistant prostate cancer and improve cancer immunotherapies in other solid tumors. Constellation also plans to progress CPI-0610 as a treatment for myelofibrosis, either as monotherapy or in combination with a JAK inhibitor. The company intends to advance a second-generation EZH2 program into the clinic and to identify additional experimental therapies from its epigenetics discovery platform. The announced $100 million financing gives Constellation additional flexibility and runway to pursue its clinical development plans. Constellation Pharma is a Cambridge-based epigenetics company developing inhibitors against BET proteins and the EZH2 histone lysine methyltransferase. Its lead asset, CPI-0610, has been in Phase 1 testing in lymphoma since September 2013 and the company has initiated two additional Phase 1 trials for multiple myeloma and for acute leukemias/myelodysplastic syndrome. The company was founded in 2008 and has received more than $50 million in funding to date; its last equity raise was in 2011. In 2012 Roche’s Genentech paid a $95 million up-front fee and secured an exclusive option to acquire Constellation while funding its research for a three-year period. Recently Constellation closed a $5 million internal round from existing investors and received a $1.5 million milestone payment from The Leukemia and Lymphoma Society tied to the new studies. The company has ties to Third Rock Ventures and has received investment from The Column Group, Venrock, SR‑One and Altitude Life Science Ventures. Constellation Pharmaceuticals discovers and develops small-molecule therapeutics that target chromatin-based (epigenetic) mechanisms to treat cancer and inflammatory/immunologic disorders. The company’s discovery engine targets enzymes that modify chromatin structure and other chromatin-interacting proteins to restore normal gene expression. Constellation says its platform has produced multiple compelling drug candidates and the company has recently added R&D leadership and achieved key internal development milestones. Proceeds from the latest financing will be used to continue advancing product candidates toward clinical development. The company emphasizes selective, specific inhibitors as the path to new medicines across a broad range of diseases. Headquartered in Cambridge, Mass., Constellation positions itself as moving from discovery toward a product-focused, clinic-directed trajectory. Constellation Pharmaceuticals is a Cambridge, Massachusetts–based biopharmaceutical company focused on discovering and developing drugs that target epigenetic regulation of the human genome. Its core approach centers on an epigenetics product engine used to probe multiple classes of novel drug targets involved in chromatin regulation and disease. The company intends to advance a pipeline of compounds toward the clinic. It raised $22M in a Series B financing to support those development plans. This financing brings the total capital raised in the two years since its founding to $54M. Proceeds will be used to advance development of its pipeline and continue applying its epigenetics platform across target classes.

Total raised

$142M

Funding rounds

4

Latest round

Equity

Latest activity

Apr 2018